Liberum Capital Reaffirms Hold Rating for AstraZeneca (LON:AZN)

Liberum Capital reiterated their hold rating on shares of AstraZeneca (LON:AZN) in a research note published on Friday, September 20th, ThisIsMoney.Co.Uk reports.

Several other brokerages also recently weighed in on AZN. JPMorgan Chase & Co. reiterated an overweight rating and issued a GBX 7,900 ($103.23) price target on shares of AstraZeneca in a report on Monday, September 16th. Jefferies Financial Group reiterated a neutral rating on shares of AstraZeneca in a report on Thursday, August 29th. Goldman Sachs Group set a GBX 5,500 ($71.87) price target on AstraZeneca and gave the stock a sell rating in a report on Monday, September 2nd. Citigroup reissued a buy rating and issued a £100 ($130.67) price objective (up previously from GBX 7,000 ($91.47)) on shares of AstraZeneca in a research note on Wednesday, September 11th. Finally, Deutsche Bank increased their price objective on AstraZeneca from GBX 7,600 ($99.31) to GBX 7,800 ($101.92) and gave the stock a buy rating in a research note on Monday, September 9th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of GBX 7,050 ($92.12).

Shares of AZN stock opened at GBX 7,383 ($96.47) on Friday. The company has a debt-to-equity ratio of 144.48, a current ratio of 0.95 and a quick ratio of 0.74. The stock’s 50 day simple moving average is GBX 7,215.79 and its two-hundred day simple moving average is GBX 6,452.32. AstraZeneca has a 1 year low of GBX 5,312 ($69.41) and a 1 year high of GBX 7,583 ($99.09). The company has a market cap of $96.86 billion and a PE ratio of 43.13.

The firm also recently disclosed a dividend, which was paid on Monday, September 9th. Stockholders of record on Thursday, August 8th were given a GBX 71.90 ($0.94) dividend. The ex-dividend date was Thursday, August 8th. This represents a dividend yield of 1.07%. AstraZeneca’s payout ratio is 1.28%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: Net Margin

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.

Leave a Reply